Top Markets
#1 MON MON +2,760.99%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.39%
#4 eCash eCash +37.30%
#5 PinGo PinGo +24.63%
#6 Siren Siren +24.18%
#7 Collector Crypt Collector Crypt +23.96%
#8 SAFEcoin SAFEcoin +19.72%
#9 Janction Janction +19.66%
#10 Velvet Velvet +15.56%
Coin of the day
MON MON
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rangering i aksjer #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aksjekurs
$0.30840035
Markedsverdi
$94.37M
Endring (1 dag)
0.00%
Endring (1 år)
-34.60%
Land
FR
Handel Sensorion SA (ALSEN)

Kategori

Healthcare
Inntekter for Sensorion SA (ALSEN)
Inntekter i Dec 2025 TTM: $-40.05M
Ifølge Sensorion SA sine nyeste økonomiske rapporter er selskapets nåværende resultat $-40.05M. I 2023 hadde selskapet et resultat på $-24.06M, en økning sammenlignet med resultatet i 2022, som var $-29.06M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Sensorion SA fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-40.05M 48.91%
2024 $-26.89M 11.77%
2023 $-24.06M -17.20%
2022 $-29.06M 40.87%
2021 $-20.63M 56.49%
2020 $-13.18M -19.26%
2019 $-16.33M 15.05%
2018 $-14.19M 22.11%
2017 $-11.62M 21.72%
2016 $-9.55M 64.80%
2015 $-5.79M 55.42%
2014 $-3.73M 64.62%
2013 $-2.26M 73.88%
2012 $-1.30M 56.52%
2011 $-832.10K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -61,819.42%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -12,998.66%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -12,976.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -5,437.79%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.66B -4,233.76%
NL